Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, Parker K, Mullins JI, Sow PS, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group..

PLoS One. 2012;7(9):e45372. doi: 10.1371/journal.pone.0045372. Epub 2012 Sep 18.

2.

Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, Sow PS, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group..

AIDS. 2011 Nov 28;25(18):2235-41. doi: 10.1097/QAD.0b013e32834d8e52.

3.

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, Starling AK, Traore F, Sall F, Wong KG, Cherne SL, Anderson DJ, Dye SA, Smith RA, Mullins JI, Kiviat NB, Sow PS; University of Washington-Dakar HIV-2 Study Group..

Clin Infect Dis. 2009 Feb 15;48(4):476-83. doi: 10.1086/596504. Erratum in: Clin Infect Dis. 2009 Mar 15;48(6):848.

4.

[Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study].

Ndour CT, Batista G, Manga NM, Guèye NF, Badiane NM, Fortez L, Sow PS.

Med Mal Infect. 2006 Feb;36(2):111-4. Epub 2006 Feb 15. French.

PMID:
16480843

Supplemental Content

Loading ...
Support Center